OBX vs GLUE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
OBX · Obsidian Therapeutics$13.87 ▲ 44.43%
GLUE · Monte Rosa Therapeutics$10.57 ▲ 3.12%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- OBX -20.7%
- GLUE -53.1%
Head to head
| Metric | OBX | GLUE |
|---|---|---|
| Price | $13.87 | $10.57 |
| Change today | ▲ 44.43% | ▲ 3.12% |
| Market cap | $856.48M | $903.21M |
| Return, 3 months | -60.4% | -33.2% |
| Return, year to date | – | -32.6% |
| Return, 1 year | – | -14.1% |
| P/E (TTM) | 21.3 | -7.6 |
| P/B | 2.4 | 1.8 |
| P/E percentile vs own 5y | 66th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -61.3% |
| Net profit growth (YoY) | +21.4% | -253.0% |
| Gross margin | – | – |
| Operating margin | – | -633.0% |
| Net margin | – | -560.9% |
| Return on equity | – | -42.7% |
| Analyst target vs. price | +207.8% | +157.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 51 | 45 |
| 30-day volatility | 145.4% | 58.0% |
| Max drawdown, 1 year | -72.6% | -61.5% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GLUE is the largest of the group by market value.
- GLUE carries the lowest trailing P/E.
- GLUE has been the calmest stock over the last 30 days.